Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.67 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454529 | 0.86 | PDPK1 (0.60) | AKT2TLK2PDPK1ALKFLT3 | |
| SCHEMBL3790960 | 0.85 | AKT2 (0.71) | AKT2TLK2PDPK1JAK3 | |
| SCHEMBL3805643 | 0.85 | MEN1 (0.68) | AKT2TLK2PDPK1JAK3MEN1 | |
| SCHEMBL4481524 | 0.82 | AKT2 (0.64) | AKT2TLK2PDPK1JAK3ALK | |
| SCHEMBL4413790 | 0.81 | MEN1 (0.73) | TLK2PDPK1JAK3ALKFLT3 | |
| SCHEMBL4413785 | 0.81 | MEN1 (0.73) | TLK2PDPK1JAK3ALKFLT3 | |
| SCHEMBL5728390 | 0.81 | AKT2 (1.00) | AKT2PDPK1 | |
| SCHEMBL5728394 | 0.81 | AKT2 (1.00) | AKT2PDPK1 | |
| SCHEMBL2114561 | 0.80 | PAK4 (0.57) | AKT2TLK2PDPK1JAK3ALK | |
| SCHEMBL31216363 | 0.79 | KDR (0.71) | AKT2TLK2PDPK1JAK3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| WO-2010120387-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1536783-B1 | SOLID FORMULATIONS COMPRISING AN INDOLINONE COMPOUND | PFIZER ITALIA SRL (IT) | 2008-08-06 | — | — | EP | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2005-08-11 | — | — | US | disclosed |
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | AKT2 223/4885TLK2 388/4885PDPK1 1/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | AKT2 154/4885TLK2 608/4885PDPK1 857/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | AKT2 205/4885TLK2 380/4885PDPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.